Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • pecanton
    Member
    • Jun 2011
    • 13

    HiSeq 3000 output FastQC parameters are bad, should I ask for resequencing?

    Recently we sent a batch of 24 samples of total RNA to a company for sequencing on a HiSeq 3000 platform. Both our own and the company's quality checks on the samples showed good integrity of RNA and very good purity, so they went ahead with library preparation and sequencing. After the wait we got a hard drive with the data. However, after running FastQC some of the plots show problematic issues which I'm hesitant to attribute to the samples, since they seem more of an issue with the flowcell and/or library preparation. The samples were sequenced for a downstream de-novo transcriptome assembly with Trinity, but I'm not sure if the sequences as they are now will be good enough for that, even after trimming off the adapter. I've attached the FastQC of two representative samples (for both forward and reverse reads, simplified file names). They were sequenced in different flow cells since all the samples were not sequenced together to have enough reads per sample when multiplexing. The most alarming things:

    - Poor per-tile quality. Some regions of the flow cells seem like they failed in the later cycles, and they are localized, as if something had failed in one particular spot and not a generalized problem. You can also see this impacting the quality per sequence plot, where there's a hump in the sample with the worse per-tile quality.

    -Adapter content. In some samples adapter starts showing up at around cycle 100, which to me suggests the fragmentation was a bit too aggressive and small fragments were used in the library preparation.

    We paid quite a bit of money to have this sequenced, and it doesn't feel like the run was up to standard. Should we go back and ask the company to re-do this?
    Attached Files
  • luc
    Senior Member
    • Dec 2010
    • 469

    #2
    Hi pecanton,

    this is a subset of the data? How many reads did you get in total?
    There was indeed an issue with the flowcell, localized low quality regions causing the low quality data. Likely Illumina would replace the reagents in this case.
    The insert size is a more difficult question. By default RNA-seq libraries always contain a majority of short reads. It depends what you discussed with them before.

    Comment

    • pecanton
      Member
      • Jun 2011
      • 13

      #3
      Thank you for replying.

      The FastQC reports I showed are not subsets, they are with all the reads for those samples. On average we got around 30-33 million reads for each sample (some up to 43 million). For the entire set of 24 samples we have around 860 million reads.

      On the matter of fragment size, I do know Illumina libraries have smaller fragments. We asked for 2 X 150 bp sequencing. The fact that the adapter shows up in a detectable percentage of the reads to me means that in the library preparation the size selection of fragments to attach the adapters included pieces of much less than 150 bp, otherwise there wouldn't be a read through into the adapter sequence in the last cycles.

      Comment

      • luc
        Senior Member
        • Dec 2010
        • 469

        #4
        Originally posted by pecanton View Post
        .....
        On the matter of fragment size, I do know Illumina libraries have smaller fragments. We asked for 2 X 150 bp sequencing. The fact that the adapter shows up in a detectable percentage of the reads to me means that in the library preparation the size selection of fragments to attach the adapters included pieces of much less than 150 bp, otherwise there wouldn't be a read through into the adapter sequence in the last cycles.
        Yes, this is certainly correct. However, RNA-seq libraries generated with most protocols have a strong bias towards smaller fragments - in contrast to genomic libraries. Please see the attached examples from Illumina and from NEB information. Shortening the fragmentation times mostly results in a more prominent tail of long fragments while retaining a majority of short fragments. Thus, moving the insert sizes to 250 and above requires severe size selection measures that will be accompanied by some loss of library complexity. We do indeed carry out such size selections for de novo transcriptome assembly purposes, but I believe we are the exception and most places will not do it. Since one throws the majority of the library with the size selection this warrants a discussion in my eyes.
        Attached Files
        Last edited by luc; 07-31-2018, 04:46 PM.

        Comment

        • pecanton
          Member
          • Jun 2011
          • 13

          #5
          I've already contacted the company that did the sequencing. However, in the worst case scenario, how can I proceed to do assembly with these reads? Should I filter all reads coming from the bad tiles or let the assembler evaluate the quality of the base in the read?

          Comment

          • luc
            Senior Member
            • Dec 2010
            • 469

            #6
            I would certainly filter the reads based on average quality scores (not losing more than
            15 % of the reads) and do some very gentle quality trimming from the 3' end.

            Comment

            • pecanton
              Member
              • Jun 2011
              • 13

              #7
              I did adapter trimming and a soft quality trimming with Trim_Galore. However, I'm still uneasy about including the sequences from the bad tiles into the assembler. You know, trash in, trash out. Is there any tool you would recommend to remove them? Should that be done before of after trimming?

              Comment

              • GenoMax
                Senior Member
                • Feb 2008
                • 7142

                #8
                You can use "filterbytile.sh" from BBMap suite.

                Has the sequence provider said anything about the possibility that there was a hardware/software problem with this run. If there was then they should re-run the samples for you for no charge. Generally Illumina provides free reagent replacements to providers when they have a maintenance contract on the sequencer (which most will).
                Last edited by GenoMax; 08-02-2018, 07:03 AM.

                Comment

                • pecanton
                  Member
                  • Jun 2011
                  • 13

                  #9
                  Thank you so much! Yes, that looks like it could do the work, and it seems we have the suite already set up in our University's cluster. I'll have to play around with the parameters, I am not too sure how strict to be given the per-tile plots I am getting.

                  I called the sequencing facility yesterday, the operations team is going over my inquiry, but they haven't gotten back. I'll get in touch again today. It is a big company, so they should have those quality assurances in place for what is clearly a technical problem on their part. On my part it is more about the time it will take to get that data (if they redo it), as we are already a little behind schedule.
                  Last edited by pecanton; 08-02-2018, 07:12 AM.

                  Comment

                  • GenoMax
                    Senior Member
                    • Feb 2008
                    • 7142

                    #10
                    As you appropriately said above:

                    You know, trash in, trash out.
                    That needs to take priority.

                    Comment

                    • pecanton
                      Member
                      • Jun 2011
                      • 13

                      #11
                      I did try to use Filter by Tile, even with the aggressive parameters they suggest, and although reduced, I still had a number of bad tiles carrying over. Fortunately, Well, after some back and forth, the company will be resequencing the samples. I'll use the ones I have to start optimizing parameters with Trinity. I've done bioinformatics before, but haven't ever done assembly with this big of a dataset, so I'll have to read around a bit.

                      Thank you all for your answers!

                      Comment

                      • GenoMax
                        Senior Member
                        • Feb 2008
                        • 7142

                        #12
                        Glad to hear they are doing the right thing and will re-sequence. Only thing you are out of is time.

                        Comment

                        Latest Articles

                        Collapse

                        • mylaser
                          Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                          by mylaser
                          Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
                          If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
                          This guide explains everything you need to know about...
                          Yesterday, 01:13 AM
                        • SEQadmin2
                          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                          by SEQadmin2



                          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                          ...
                          07-09-2026, 11:10 AM
                        • SEQadmin2
                          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                          by SEQadmin2



                          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                          07-08-2026, 05:17 AM

                        ad_right_rmr

                        Collapse

                        News

                        Collapse

                        Topics Statistics Last Post
                        Started by SEQadmin2, 07-09-2026, 10:04 AM
                        0 responses
                        21 views
                        0 reactions
                        Last Post SEQadmin2  
                        Started by SEQadmin2, 07-08-2026, 10:08 AM
                        0 responses
                        13 views
                        0 reactions
                        Last Post SEQadmin2  
                        Started by SEQadmin2, 07-07-2026, 11:05 AM
                        0 responses
                        31 views
                        0 reactions
                        Last Post SEQadmin2  
                        Started by SEQadmin2, 07-02-2026, 11:08 AM
                        0 responses
                        31 views
                        0 reactions
                        Last Post SEQadmin2  
                        Working...